Trial · NCT03985943
Participant flow48
How many started, completed or left each group, period by period.
1 to 20 of 48
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Initial Treatment(Day 1-Week 16 Predose) | STARTED | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 321 | |
| Initial Treatment(Day 1-Week 16 Predose) | STARTED | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 620 | |
| Initial Treatment(Day 1-Week 16 Predose) | STARTED | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | STARTED | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | STARTED | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | STARTED | Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | Safety Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 321 | |
| Initial Treatment(Day 1-Week 16 Predose) | Safety Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 616 | |
| Initial Treatment(Day 1-Week 16 Predose) | Safety Population | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | Safety Population | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | Safety Population | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | Safety Population | Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | COMPLETED | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 296 | |
| Initial Treatment(Day 1-Week 16 Predose) | COMPLETED | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 560 | |
| Initial Treatment(Day 1-Week 16 Predose) | COMPLETED | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | COMPLETED | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | COMPLETED | Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | COMPLETED | Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W | 0 | |
| Initial Treatment(Day 1-Week 16 Predose) | NOT COMPLETED | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 25 | |
| Initial Treatment(Day 1-Week 16 Predose) | NOT COMPLETED | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 60 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03985943/flow